NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

Yes-associated protein (YAP) is a downstream target of the Hippo pathway and has been found to be oncogenic driving many cancers into developing metastatic phenotypes leading to poor survival outcomes. This study investigated if YAP expression is associated with drug resistance in two non-small cell lung cancer (NSCLC) lines (HCC827 and H1975) generated to become resistant to the EGFR tyrosine kinase inhibitors (EGFR TKI) erlotinib, gefitinib or the T790M-specific osimertinib. We found that acquired EGFR TKI resistance was associated with YAP over-expression (osimertinib-resistant cells) or YAP amplification (erlotinib- and gefitinib-resistant cells) along with EMT phenotypic changes. YAP was localized in the nucleus, indicative of active protein. siRNA-mediated silencing of YAP resulted in re-sensitizing the drug-resistant cells to EGFR TKI compared to the negative siRNA controls (p = <0.05). These results suggest YAP is a potential mechanism of EGFR-TKI resistance in NSCLC and may presents itself as a viable therapeutic target.

[1]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[2]  Shu Liu,et al.  YAP promotes erlotinib resistance in human non-small cell lung cancer cells , 2016, Oncotarget.

[3]  O. Brustugun.  Stratification in advanced non-small cell lung cancer: precision medicine in practice , 2016 .

[4]  Yasufumi Yamamoto,et al.  Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers , 2015, FEBS open bio.

[5]  V. Adamo,et al.  A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives , 2015, Oncotarget.

[6]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  E. Smit,et al.  Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. , 2014, Lung cancer.

[9]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[10]  S. Dedhar,et al.  Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase , 2013, Nature Communications.

[11]  Y. Miyagi,et al.  Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells , 2013, Laboratory Investigation.

[12]  X. Chen,et al.  Yes-Associated Protein 1 Promotes Adenocarcinoma Growth and Metastasis through Activation of the Receptor Tyrosine Kinase Axl , 2012, International journal of immunopathology and pharmacology.

[13]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[14]  Nam‐Gyun Kim,et al.  E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components , 2011, Proceedings of the National Academy of Sciences.

[15]  S. Lowe,et al.  AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.

[16]  R. Goldman,et al.  Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  E. Wang,et al.  Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer , 2010, Cancer science.

[18]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[19]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[20]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[21]  G. Clark,et al.  Effects of Smoking on the Pharmacokinetics of Erlotinib , 2006, Clinical Cancer Research.

[22]  D. Kerr,et al.  Single-Dose Clinical Pharmacokinetic Studies of Gefitinib , 2005, Clinical pharmacokinetics.